bimekizumab,adalimumab
ucb pharmaceuticals,abbvie
['be optimal', 'bimekizumab']
congress #acr22 | christopher t. ritchlin discussed the phase iii be optimal study of bimekizumab in pts with active #psoriaticarthritis. ~90% of patients completed the study up to week 52, with low discontinuation due to teaes. 
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education.